Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Call Transcript
10:15pm, Friday, 04'th Nov 2022
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive O
Ascendis Pharma: Translating Valuable IP Into A Profitable Business
12:17pm, Friday, 04'th Nov 2022
Ascendis Pharma has one commercial product and another with a PDUFA date in early 2023 and a path to profitability. The validated platform has produced best in class medicines and in Q4 there will be
Ascendis Pharma: TransCon CNP Data Coming Q4
12:42pm, Thursday, 15'th Sep 2022
Ascendis Pharma is now a commercial-stage company with a full pipeline and a revenue stream. There are multiple upcoming catalysts, including oncology data due by year end, which may validate the brea
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2022 Results - Earnings Call Transcript
10:36pm, Wednesday, 10'th Aug 2022
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive
Why Ascendis Pharma Stock Is Sinking Today
12:46pm, Thursday, 12'th May 2022
Investors are reacting negatively to the company's Q1 update.
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2022 Results - Earnings Call Transcript
11:29pm, Wednesday, 11'th May 2022
Ascendis Pharma A/S (ASND) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jan Mikkelsen – President and Chief Executive Officer Scott T. Smith – Senior Vice Presiden
Why Ascendis Pharma (ASND) Might Surprise This Earnings Season
03:46am, Wednesday, 11'th May 2022
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma: Biotech Bear Provides Attractive Entry Point
06:00am, Monday, 09'th May 2022
Shares have lost nearly 40% of their value year to date. I provide a recap of the bullish thesis, which has strengthened considerably with conclusive phase 3 data for TransCon PTH.
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
11:00am, Sunday, 01'st May 2022 GlobeNewswire Inc.
New data highlights include:
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
07:00am, Sunday, 01'st May 2022
New data highlights include:
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
02:41am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candi
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
08:01pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candi
ADRs End Mostly Lower; Ascendis Pharma, Infosys Trade Actively - Morningstar
03:18pm, Wednesday, 16'th Mar 2022 Morningstar
ADRs End Mostly Lower; Ascendis Pharma, Infosys Trade Actively Morningstar
Ascendis posts biggest intraday gain in six months as BofA upgrades on trial results
07:58pm, Tuesday, 15'th Mar 2022 Seeking Alpha
The ADRs of Ascendis Pharma (ASND) have recorded the biggest intraday gain since August on Tuesday after Bank of America upgraded the Danish biotech citing “positive” results from a…
